Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

Br J Cancer. 2001 Nov 30;85(11):1753-8. doi: 10.1054/bjoc.2001.2139.

Abstract

c-Raf is an essential component of the extracellular related kinase (ERK) signal transduction pathway. Immunohistochemical staining indicated that c-Raf was present in 49/53 ovarian adenocarcinomas investigated and high c-Raf expression correlated significantly with poor survival (P = 0.002). c-Raf protein was detected in 15 ovarian cancer cell lines. Antisense oligodeoxynucleotides (ODNs) (ISIS 5132 and ISIS 13650) reduced c-Raf protein levels and inhibited cell proliferation in vitro. Selectivity was demonstrated by the lack of effect of ISIS 5132 on A-Raf or ERK, while a random ODN produced only minor effects on growth and did not influence c-Raf expression. ISIS 5132 produced enhanced apoptosis and cells accumulated in S and G(2)/M phases of the cell cycle. In vivo, ISIS 5132 inhibited growth of the s.c. SKOV-3 xenograft while a mismatch ODN had no effect. These data indicate that high levels of c-Raf expression may be important in ovarian cancer and use of antisense ODNs targeted to c-Raf could provide a strategy for the treatment of this disease.

MeSH terms

  • Animals
  • Cell Cycle / drug effects
  • Cell Cycle / physiology
  • Cell Division / drug effects
  • DNA, Antisense / pharmacology*
  • DNA, Antisense / therapeutic use
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Immunohistochemistry
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / pathology
  • Proto-Oncogene Proteins c-raf / biosynthesis
  • Proto-Oncogene Proteins c-raf / drug effects*
  • Proto-Oncogene Proteins c-raf / genetics
  • Survival Analysis
  • Time Factors
  • Xenograft Model Antitumor Assays

Substances

  • DNA, Antisense
  • Proto-Oncogene Proteins c-raf